Soaanz is a drug owned by Sarfez Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 06, 2033. Details of Soaanz's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10154963 | Controlled-release formulations comprising Torsemide |
Oct, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Soaanz's patents.
Latest Legal Activities on Soaanz's Patents
Given below is the list of recent legal activities going on the following patents of Soaanz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 17 Aug, 2022 | US10154963 |
| Surcharge for late Payment, Small Entity | 17 Aug, 2022 | US10154963 |
| Maintenance Fee Reminder Mailed Critical | 08 Aug, 2022 | US10154963 |
| Change in Power of Attorney (May Include Associate POA) Critical | 17 Sep, 2021 | US10154963 |
| Correspondence Address Change Critical | 15 Sep, 2021 | US10154963 |
| Patent Issue Date Used in PTA Calculation Critical | 18 Dec, 2018 | US10154963 |
| Recordation of Patent Grant Mailed Critical | 18 Dec, 2018 | US10154963 |
| Email Notification Critical | 29 Nov, 2018 | US10154963 |
| Issue Notification Mailed Critical | 28 Nov, 2018 | US10154963 |
| Dispatch to FDC | 14 Nov, 2018 | US10154963 |
US patents provide insights into the exclusivity only within the United States, but Soaanz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Soaanz's family patents as well as insights into ongoing legal events on those patents.
Soaanz's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Soaanz's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 06, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Soaanz Generic API suppliers:
Torsemide is the generic name for the brand Soaanz. 9 different companies have already filed for the generic of Soaanz, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Soaanz's generic
About Soaanz
Soaanz is a drug owned by Sarfez Pharmaceuticals Inc. Soaanz uses Torsemide as an active ingredient. Soaanz was launched by Sarfe Pharms in 2021.
Approval Date:
Soaanz was approved by FDA for market use on 14 June, 2021.
Active Ingredient:
Soaanz uses Torsemide as the active ingredient. Check out other Drugs and Companies using Torsemide ingredient
Dosage:
Soaanz is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 60MG | TABLET | Discontinued | ORAL |
| 20MG | TABLET | Discontinued | ORAL |